More than half of its gross sales ultimately went to payers as rebates, Sanofi says
In a new report, Sanofi is adding another data point to one of pharma’s go-to defenses regarding their pricing practices.
As much as 55% of its gross sales in 2019 were given back to payers in the form of rebates, the pharma giant disclosed, including $5.5 billion in mandatory rebates to the government and $8.4 billion in discretionary rebates to insurance companies.
Once that is taken into account, the average aggregate net price of Sanofi’s portfolio of drugs — distinct from the list price, which went up by 2.9% — recorded a 11.1% decrease last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
